NCT02083627View on ClinicalTrials.gov

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Drug-Drug Interaction (DDI)Intestinal AbsorptionHealthy SubjectsPharmacokinetics of RosuvastatinPharmacokinetics of Fidaxomicin

Interventions

DRUG

rosuvastatin

Oral

DRUG

fidaxomicin

Oral

Trial Locations (1)

D-14059

Parexel GmbH, Berlin

All Listed Sponsors

collaborator

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02083627 - A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects | Biotech Hunter | Biotech Hunter